Yamo Pharmaceuticals
Yamo Pharmaceuticals is developing L1-79, a novel therapy that targets the core symptoms of autism and has been well-tolerated by clinical trial patients to-date. The mechanism of action for L1-79 addresses both the central nervous system and metabolic symptoms of autism.
7-day free trial · no credit card
Verified contacts
5
available on Kipplo
LinkedIn employees
8
1 to 10 range
Open roles
—
no listings
Distinct roles
2
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 5 verified contacts at Yamo Pharmaceuticals
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
5 contacts with verified email or phone · masked until revealed.
- EP
Eugene Prahin
Chief Financial Officer · Finance & Accounting
EmailPhone - NF
Natalie Farris
Vice President of Cmc · Science
EmailPhone - NF
Natalie Farris
Vice President of Cmc · Science
EmailPhone
Showing 3 of 5 verified contacts
Top roles at Yamo Pharmaceuticals
2 distinct titles indexed · top 2 shown.
- 2vice president of cmc
- 1chief financial officer
Sign up to unlock all 5 contacts at Yamo Pharmaceuticals
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 5 verified contacts at Yamo Pharmaceuticals
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.